SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is trending as a potential solution to increase transaction speeds and enhance regulatory compliance in blockchain, with some community members suggesting it could complement larger crypto projects like NVDA, SUI, and BTC. Its focus on institutional financial infrastructure and integrations with companies like Stripe are also key talking points. However, some users express concern regarding the project.

Power & Digital Infrastructure Acquisition Corp. operates as a blank check company. The firm engages in seeking a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or entities. The company was founded on December 29, 2020 and is headquartered in Chicago, IL.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

Core Scientific (CORZ) is trending as investors digest the implications of a failed merger, with the community now speculating on new customer announcements and financing opportunities. Bullish sentiment suggests the company is undervalued, especially given its AI infrastructure and power pipeline, leading to discussions about potential upside into 2026. Some are hopeful for new deals that could drive the stock higher, while others are critical of management's strategy.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as investors discuss the potential impact of a move to the Nasdaq exchange and speculate about upcoming OEM partnerships, particularly with the inauguration of the Eagle Line facility approaching in February 2026. The community's focus is on the company's technology, scaling roadmap, and anticipated announcements, with bullish investors expressing confidence in QuantumScape's long-term potential in the solid-state battery market.

Avalanche is a high throughput smart contract blockchain platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is trending as community members discuss its potential alongside emerging Layer 1 solutions like Keeta, particularly regarding high-throughput capabilities and institutional adoption. Community talking points highlight Avalanche's subnet architecture versus Keeta's focus on compliance-ready financial infrastructure. Keeta's integration with Stripe's Bridge for fiat on/off-ramps is also sparking interest as a catalyst for institutional flows.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation that cannabis could be reclassified, potentially easing tax burdens and banking restrictions for cannabis companies. The community is discussing potential price targets and whether this rally has staying power, with some citing historical runs and short squeeze potential. However, some caution against hype, noting the reverse stock split and potential for dilution.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

Yee Token is trending as community members rally behind the token's potential within the Ethereum ecosystem, citing a long-term prophecy and strong community support. Social media buzz suggests growing confidence and anticipation for significant expansion, with some drawing comparisons to other successful meme coins. The community emphasizes the token's role in the broader ETH narrative, attracting attention from traders.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FCEL is trending as investors discuss its potential role in powering AI data centers using natural gas and carbon capture technology, particularly following positive mentions from ExxonMobil's recent earnings call. Community members are weighing the company's prospects against competitors like Bloom Energy, with some anticipating significant upside if FCEL secures major contracts in the expanding AI energy market. Discussions also include the stock's volatile history and the impact of past dilutions on its current valuation.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

PumpMindVirus ($PMV) is trending as its community rallies around its meme-focused culture and energetic online presence, emphasizing the "infection" and "pressure" it brings to the Solana ecosystem. The community is actively spreading memes and expressing excitement about its potential, aiming to bring fun and energy to the crypto space, with some even touting it as a top meme coin for 2026. Discussions highlight the coin's strong community and the "viral" spread of its memes.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending as investors react to speculation around potential federal cannabis policy changes, including a possible executive order from President Trump. Community members are discussing the implications of rescheduling for US cannabis companies and whether this time could be different after years of false starts. Talk centers on potential catalysts like the Supreme Court taking up the cannabis case and the impact on profitability due to tax code changes.

Advisorshares Trust - AdvisorShares MSOS 2x Daily ETF

AdvisorShares MSOS Daily Leveraged ETF

MSOX is trending as traders discuss the potential impact of cannabis rescheduling, with some citing Trump's recent comments as a possible catalyst. The community is weighing the risks and rewards of this leveraged ETF, with many expressing confidence in a sector-wide rally. However, some traders remain cautious, pointing to historical volatility and potential reverse splits.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Average Rating of "Moderate Buy" from Analysts

Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) have received an average recommendation of "Moderate Buy" from the six brokerages that are presently covering the firm, Marketbeat...

BTIG Research Reiterates Buy Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

BTIG Research reaffirmed a "buy" rating and set a $25.00 price objective on shares of NRx Pharmaceuticals in a research report on Wednesday...

What is HC Wainwright's Forecast for NRXP FY2025 Earnings?

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Free Report) - Equities researchers at HC Wainwright cut their FY2025 earnings per share estimates for shares of NRx Pharmaceuticals in a report issued on...

NRx Pharmaceuticals (NASDAQ:NRXP) Upgraded at Wall Street Zen

Wall Street Zen raised NRx Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Sunday...

NRx Pharmaceuticals (NASDAQ:NRXP) Issues Earnings Results

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of...

NRx Pharmaceuticals (NASDAQ:NRXP) Downgraded by Wall Street Zen to "Sell"

Wall Street Zen lowered NRx Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday...

D. Boral Capital Reiterates "Buy" Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

D. Boral Capital reiterated a "buy" rating and set a $34.00 target price on shares of NRx Pharmaceuticals in a research note on Monday...

Retail buzz around NRx Pharmaceuticals picked up Monday after the company said that the U.S. Food and Drug Administration (FDA) granted fast-track designation to its NRX-100 therapy for treating suicidal thoughts in patients with depression, including bipolar depression.The new designation means NRX-100 could be used to treat about 13 million Americans who consider suicide each year, which is 10x more than under its 2017 designation, which covered only bipolar depression when combined with NRX-101.However,&nbsp;<a href="https://stocktwits.com/symbol/NRXP">NRx Pharmaceuticals’ stock</a> closed down 7.9% at $0.2 on Monday, then inched up 0.2% in after-hours trading.The FDA determined NRX-100 has the potential to address an unmet medical need, making the drug eligible for the Commissioner’s National Priority Voucher (CNPV) program and the agency’s Accelerated Approval pathway.&nbsp;NRx said it has applied for a CNPV, which could shorten the review cycle.The company cited multiple controlled trials submitted to the FDA that showed clinically meaningful reductions in suicidal ideation with intravenous ketamine. In a Columbia University study licensed by NRx, 55% of patients met the response criteria compared with 30% for an active comparator.&nbsp;In a French government-sponsored study also licensed by NRx, 63% of participants achieved remission within three days, compared to 31% for the placebo group.CEO Jonathan Javitt said the designation was a “significant step forward” in addressing suicide risk among soldiers, veterans, first responders, and civilians. NRx plans to post an expanded access policy for NRX-100 within two weeks and will meet with the FDA to finalize the data package for its Accelerated Approval and CNPV application.The company noted&nbsp;that NRX-100 is the first preservative-free ketamine presentation filed with the FDA. Current ketamine products often contain benzethonium chloride, a preservative not recognized as safe by the FDA.&nbsp;NRx has petitioned the FDA to ban the compound from all intravenous ketamine products and has started producing sterile, preservative-free ketamine in the U.S.Roughly 13 million U.S. adults seriously think about suicide each year, with 1.5 million attempts and one life lost every 11 minutes, the company said in a statement, citing the CDC.NRx pointed out that while the Department of Veterans Affairs and the Department of Defense cover intravenous ketamine, most insurers won’t pay for it as it’s only officially approved as an anesthetic.The fast-track designation provides drugmakers with closer contact with the FDA, the opportunity to qualify for Priority Review and Accelerated Approval if certain requirements are met, and the option to submit parts of an application for review as they are completed.On Stocktwits, retail sentiment for NRx Pharmaceuticals was ‘extremely bullish’ late Monday amid ‘extremely high’ message volume.NRx Pharmaceuticals’ stock has risen 5.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail buzz around NRx Pharmaceuticals (NRXP) picked up Monday after the company said that the U.S. Food and Drug Administration (FDA) granted fast-track designation to its NRX-100 therapy. (Photo credit: Getty Images)

Why Small-Cap Biotech NRx Pharmaceuticals Is Drawing Heavy Retail Buzz 

NRx said the FDA’s fast-track status makes NRX-100 eligible for the Commissioner’s National Priority Voucher program and the FDA’s Accelerated Approval pathway, and the company has already applied for a CNPV.

Equity

NRx Pharmaceuticals Inc. (NRXP) (+900% Weekly Message Volume)The Wilmington, Delaware-based pharma company garnered retail attention after the FDA granted it a $4.3 million filing fee waiver for its New Drug Application (NDA) for NRX-100, a preservative-free ketamine treatment for depression.&nbsp;The company aims to file the NDA using existing resources by the end of Q2. If approved, the drug could gain long-term exclusivity.&nbsp;NRx plans to submit data showing NRX-100 is superior to placebo, an active comparator, and potentially even electroshock therapy for treatment-resistant depression and suicidal ideation.<a href="https://stocktwits.com/symbol/NRXP">NRx stock</a> has fallen over 2.8% this year.CVS Health Corp. (CVS) (+650% Weekly Message Volume)The health solutions giant&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cvs-reports-upbeat-q1-earnings-raises-full-year-guidance/chLv3eARbit">posted</a> strong first-quarter results, with all three divisions (healthcare benefits, health services, and pharmacy) beating Wall Street expectations.&nbsp;Retail buzz also intensified after its pharmacy benefits unit struck a deal to make Wegovy more accessible to members, replacing Zepbound as the preferred drug — a move expected to save health plans up to 15% on annual costs.&nbsp;Stocktwits chatter was also fueled by a DOJ lawsuit against Aetna and other insurers, accusing them and major broker firms of paying illegal kickbacks for Medicare Advantage enrollments between 2016 and 2021.<a href="https://stocktwits.com/symbol/CVS">CVS stock</a> has gained nearly 50% this year.&nbsp;ReShape Lifesciences Inc. (RSLS) (+600% Weekly Message Volume)ReShape Lifesciences gained attention with new preclinical data on its Diabetes Neuromodulation&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rsls-stock-soars-on-us-patent-for-diabetes-neuromodulation-system/chQSOp9RbQM">device</a>, showing promising results in stabilizing glucose and glucagon levels in Type 1 diabetic swine without affecting heart rate.&nbsp;Investors also reacted to news that the company received a Notice of Allowance from the United States Patent and Trademark Office for a patent covering its swallowable intragastric balloon system. This patent could potentially protect the technology until at least January 2031.<a href="https://stocktwits.com/symbol/RSLS">ReShape shares</a> have tumbled over 90% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Wilmington, Delaware-based NRx Pharmaceuticals registered the biggest spike in retail message volume among healthcare stocks last week.  | Image source: Getty Images

Stocktwits Spotlight: NRx, CVS, ReShape Lead Weekly Jump In Health Care Stock Chatter

Favorable regulatory moves for a new drug application, blowout earnings and promising preclinical data triggered a flurry of discussions on Stocktwits for these tickers for the week ended April 11, 2025.  

Favorable regulatory moves for a new drug application, blowout earnings and promising preclinical data triggered a flurry of discussions on Stocktwits for these tickers for the week ended May 2, 2025.  

Shares of NRx Pharmaceuticals Inc. surged nearly 25% on Tuesday, its best session in&nbsp;almost three weeks, drawing heavy interest from retail traders.The surge followed news of a $27 million funding deal to fund the company’s planned purchase of Hope clinics.NRx’s Hope Therapeutics unit announced a stock purchase agreement with Smith &amp; Sauer, a private investment firm specializing in healthcare and technology investments.&nbsp;The agreement includes an immediate $2 million investment in NRx common stock and a $25 million purchase of Hope’s Series A preferred shares, with $6.75 million due by Feb. 7 and the remainder by April 1.&nbsp;The funds will be used to expand Interventional Psychiatry Clinics focused on treating severe depression and other psychological disorders.Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold.&nbsp;He added that the company had initiated a financial advisory relationship to raise an additional $400 million for broader expansion.&nbsp;"Psychedelic Medications such as ketamine, neuromodulation technologies such as TMS, and digital therapeutics have sparked a revolution in psychiatry where for the first time patients with life threatening conditions such as depression and PTSD hope for a brighter future,” he said.Retail traders on Stocktwits took note, with message volume surging 94% on Tuesday and remaining at high levels ahead of Wednesday’s market open.&nbsp;Sentiment on the stock turned ‘bullish,’ with investors speculating on the impact of the projected $100 million revenue on earnings and share price.&nbsp;One user even predicted that the stock could more than double from current levels.<stembedurl>https://stocktwits.com/jonny80s/message/601877421</stembedurl><stembedurl>https://stocktwits.com/TheRealBomb/message/601781798</stembedurl>Despite losing 11% in value over the past year, NRx Pharmaceuticals has seen a 177% gain in the past three months, driven by increasing retail interest.&nbsp;The company’s follower count on Stocktwits has risen 3% over the last 12 months, while message volume has jumped 188%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Small-Cap NRx Pharma’s Stock Draws Heavy Retail Buzz After Securing $27M Funding 

Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold. 

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded by Jonathan C. Javitt on September 18, 2017 and is headquartered in Wilmington, DE.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	--	-$0.15	--	N/A
Q4 '25	$0.01	--	--	N/A
Q3 '25	-$0.13	-$0.27	-107.69%	MISSED
Q2 '25	-$0.15	-$0.98	-552.68%	MISSED
Q1 '25	-$0.28	-$0.34	-20.00%	MISSED

NRXP
NRX Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest NRXP News

NRXPNRX Pharmaceuticals Inc